A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of ketamine in subjects with treatment-resistant depression

ID Number 12-1582

Principal Investigator(s)
James Murrough

Department(s) or Division(s)


The primary objective of this study is to evaluate the efficacy of intravenous (IV) ketamine administered 2 or 3 times a week for 4 weeks for the treatment of treatment-resistant depression. The study involves 4 weeks of either active ketamine or placebo. After 2 weeks of non-response, participants are eligible to enter a 2-week open label phase in which they would receive active intravenous ketamine. Exploratory objectives include assessing the duration of improvement in depressive symptoms and to evaluate the effect of multiple doses of intravenous ketamine on plasma glycine, inflammatory and neurotrophic biomarkers.

Contact Information
Joanna Kim
(212) 241-6349

Recruiting Patients: No